Wear particle-induced inflammation is a major factor contributing to aseptic loosening in peri-prosthetic tissue. The effects of cannabinoid receptor 2 (CB 2 ) on wear particle-induced inflammation remain unclear. Reverse transcriptionpolymerase chain reaction and enzymelinked immunosorbent assay were used to assess the effects of a CB 2 -selective antagonist, AM630, on regulation of the inflammatory reaction and production of pro-inflammatory cytokines in response to in vitro and in vivo stimulation with titanium particles. In vitro studies, in a model for pre-osteoclast-like cells, demonstrated that AM630 inactivation of CB 2 profoundly inhibited interleukin (IL)-1b and tumour necrosis factor (TNF)-a production by RAW264.7 cells stimulated with titanium particles. In vivo findings in a murine air-pouch model of titaniuminduced inflammatory osteolysis indicated that AM630 reduced titaniuminduced tissue inflammation, seen as a reduction in pouch membrane thickness, inflammatory infiltration and levels of the pro-inflammatory cytokines IL-1b and TNF-a. Thus, inactivation of CB 2 by AM630 inhibited the titanium particleinduced inflammatory reaction by reducing pro-inflammatory cytokines in vitro and in vivo.
Introduction
Wear particle-induced osteolysis and subsequent aseptic loosening are associated with chronic inflammation in peri-prosthetic tissue. 1 − 3 These phenomena have been attributed to a tissue inflammatory response provoked by the generation of implant wear particles. Phagocytes in the tissue adjoining the implant site engulf small particles and repeated phagocytosis results in activated cells that secrete high levels of inflammatory cytokines (such as interleukin-1β [IL-1β] and tumour necrosis factor-α [TNF-α]) which may, in turn, contribute to the osteolytic process by providing activation signals to osteoclasts. 4 There is strong evidence that F Zhou, J Lu, X Zhu et al.
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TNF-α receptor knock-out mice are partially protected from particle-induced osteolysis in the murine calvaria model. 5 Moreover, blockage of TNF-α or IL-1β activity inhibits both osteoclast differentiation and particleinduced inflammation. 6 − 9 This suggests that mitigating the inflammatory response to wear particles could be a promising therapeutic method for the treatment of aseptic loosening.
The cannabinoid receptor (CB) system has been implicated in a wide range of physiological and pathological processes. 10 Two cannabinoid receptors, CB 1 and CB 2 , both of which are inhibitory G proteincoupled receptors, have been cloned: CB 1 is predominantly expressed in the brain and peripheral neurons and is responsible for the psychotropic action of cannabinoids; 10 CB 2 is expressed mainly in peripheral tissue, in particular by immune cells, 11 osteoclasts and macrophages. 12 − 15 Previous work has demonstrated that CB 2 is significantly upregulated in an air-pouch model following injection of titanium particles (titanium particles can strongly increase the expression of pro-inflammatory cytokines) 16 -18 and blockage of CB 2 with AM630 significantly reduced osteolysis induced by titanium particles. 19 Several studies have shown that CB 2 -selective antagonists also inhibit TNF-α and IL-1β production. 20, 21 There is, however, little information about the role played by CB 2 in wear particle-induced inflammation. Thus, the purpose of the present study was to determine the effects of a CB 2 -selective antagonist, AM630, on the production of the pro-inflammatory cytokines, TNF-α and IL-1β, in in vivo and in vitro models of wear particle-induced osteolysis.
Materials and methods

TITANIUM PARTICLES
Commercial pure titanium particles (Johnson Matthey, Ward Hill, MA, USA) were used in this study. According to the manufacturer, the average diameter of the titanium particles was 4.50 µm. The particles were sterilized by baking at 180°C for 6 h, followed by treatment with 70% ethanol for 48 h. The particle suspension was determined to be endotoxin-free by the Limulus assay (QCL-1000; BioWhittaker, Walkersville, MD, USA). The sterile particles were suspended in 10 mM phosphatebuffered saline (PBS), pH 7.4, and stored at 4°C before use.
IN VITRO CELL CULTURE
A murine macrophage cell line, RAW264.7, was used as an in vitro model for preosteoclast-like cells. Briefly, RAW264.7 cells were plated at a density of 1 × 10 4 cells/ml in 100 µl Dulbecco's Modified Eagle's Medium supplemented with 10% fetal bovine serum, 100 U/ml penicillin and 100 mg/ml streptomycin in six-well tissue culture dishes, and cultured in a humidified atmosphere of 5% carbon dioxide at 37°C for 18 -24 h to allow cell adherence. Then the cells were cultured in the same medium in the presence of receptor activator of nuclear factor-κB ligand (RANKL; 50 ng/ml), with or without the addition of titanium particles (0.1 mg/ml) and AM630 (0, 50, 100 and 200 nM). After 12 and 24 h of culture, the cell supernatants were collected for analysis of cytokine protein levels and the cells were harvested for mRNA analysis. The supernatants were centrifuged at 2500 g for 10 min and stored at -80°C until analysis.
IN VIVO AIR-POUCH MODEL INJECTED WITH TITANIUM PARTICLES
All animals were treated according to the principles and procedures approved by the First Affiliated Hospital of Soochow F Zhou, J Lu, X Zhu et al.
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University, Jiangsu, China.
Particle-induced inflammation was evaluated in vivo using a murine air-pouch model of titanium-induced inflammatory osteolysis as previously described. 19 The air pouches were generated in female BALB/c mice (aged 6 − 8 weeks) and, after 6 days, a 0.5-cm incision overlying the pouch was made and a section of calvaria bone (0.4 × 0.25 cm), surgically removed from syngeneic littermates, was inserted into the pouch using a sterile procedure. Titanium particles (5 mg suspended in 0.5 ml saline) were injected into the pouches 2 days later to provoke inflammation and osteolysis; pouches injected with saline alone were used as controls. For the mice that were to receive treatment, the CB 2 -selective antagonist, AM630 (200 µg/kg per day), was injected into the pouches. This started 2 days before the titanium particle injection (i.e. on the day of the calvaria bone insertion) and continued until sacrifice of the animals, 14 days after bone implantation. 12, 19 Each group (negative controls, titanium particles only, and titanium particles plus AM630 daily injections) comprised 10 mice. At sacrifice, the pouch membranes containing the implanted bone were harvested. A small portion of the pouch tissue was collected for molecular analysis and the remainder of the pouch tissue, with intact bone implant, was fixed in 10% formalin for paraffin embedding.
HAEMATOXYLIN AND EOSIN STAINING
Paraffin embedded sections (6 µm) were stained with haematoxylin and eosin to evaluate pouch membrane inflammation and cellular infiltration. Pouch thickness was determined at six points on each section, with an even distribution of measurements on the proximal side, distal side and transition curve of the pouch.
REAL-TIME QUANTITATIVE RT-PCR
Real time reverse transcription-polymerase chain reaction (RT-PCR) was used to assess the levels of IL-1β and TNF-α mRNA in the RAW264.7 cells and samples of pouch tissue. Pouch tissue (100 mg) was homogenized and RAW264.7 cells were collected after the 12 and 24 h incubation periods and total RNA was extracted using TRIzol ® reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's recommendations. Reverse transcription was performed in a 20µl reaction system with 2 µg total RNA treated with RNase-free DNase I (Takara Bio, Dalian, China) according to the manufacturer's instructions. The RT-PCR was performed on a Takara TP800 PCR thermal cycler dice detection system with SYBR ® Premix Ex Taq™ (Takara Bio) according to the manufacturer's instructions. Primers used in this study were: IL-1β, AGGCCACAGGTATTTTGTCG (forward primer) and GCCCATCCTCTGTGACTCAT (reverse primer); TNF-α, AGGGTCTGGGCCA TAGAACT (forward primer) and CCACCA CGCTCTTCTGTCTAC (reverse primer); and the housekeeping gene glyceraldehyde 3phosphate dehydrogenase which was used as an internal control, CCAATATGATT CCACCCATG (forward primer) and GAG AAGGCTGGGGCTCATTT (reverse primer). The cycling programme involved preliminary denaturation at 95°C for 10 min, followed by 40 cycles of denaturation at 95°C for 15 s, annealing at 60°C for 30 s and elongation at 72°C for 30 s, followed by a final elongation step at 72°C for 10 min.
To determine the relative level of gene expression, the comparative C T (threshold cycle) method with arithmetic formulae was used. 22 The C T of the housekeeping gene was subtracted from the C T of the target gene to yield the ∆C T for each group, which was then entered into the equation 2 -∆∆CT and used to F Zhou, J Lu, X Zhu et al.
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calculate the exponential amplification of the PCR. The gene activity in the control group was arbitrarily assigned a value of 1 to serve as a reference. The expression of the target gene from the experimental groups, therefore, represents the fold difference in expression relative to the reference gene.
ELISA
The concentrations of TNF-α and IL-1β in the supernatants of pouch tissue homogenates and cell culture supernatants were detected using enzyme-linked immunosorbent assay (ELISA) kits (BioLegend, San Diego, CA, USA) according to the manufacturer's instructions. The optical density of the colour reaction was detected at 450 nm. The limits of sensitivity of the kits were 2 and 15 pg/ml for TNF-α and IL-1β, respectively.
STATISTICAL ANALYSIS
The mean ± SD of the data were calculated and statistical analyses were carried out using the SPSS ® statistical package, version 11.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . Statistical differences between the groups were calculated with the Student's ttest. A P-value < 0.05 was considered to be statistically significant.
Results
AM630 REDUCTION OF IL-1b AND TNF-a IN VITRO
After 12 h of culture, the mRNA and protein levels of the pro-inflammatory cytokines IL-1β and TNF-α were significantly higher in RAW264.7 cells treated with titanium particles than in saline controls (P < 0.05; Fig. 1) . The levels were observed to increase 
AM630 REDUCTION OF INFLAMMATORY REACTION AND IL-1b AND TNF-a IN VIVO
As shown in Fig. 2 , calvaria bone implanted murine air pouches injected with titanium particles developed pronounced erythematous and oedematous changes compared with saline injected control pouches. The inclusion of AM630 ameliorated the inflammation within the pouch.
Haematoxylin and eosin staining revealed that titanium particle-induced tissue inflammation was characterized by increased inflammatory cellular infiltration and membrane proliferation (Fig. 3A) . Quantitative image analysis of the histological sections revealed that the membrane thickness of the pouches stimulated with titanium particles was significantly increased compared with those of the saline control group (P < 0.05; Fig. 3B ).
Treatment with AM630 significantly decreased the titanium particle-induced membrane thickness and inflammatory cellular infiltration (P < 0.05; Fig. 3B ).
Titanium particle-induced tissue inflammation was associated with local accumulation of the pro-inflammatory cytokines, IL-1β and TNF-α. Real-time RT-PCR analysis showed that exposure to titanium particles significantly increased both IL-1β (by 9.3-fold) and TNF-α (by 11.4fold) mRNA levels in the pouch tissue compared with controls (P < 0.05; Fig. 4A ). This increase was significantly reduced by AM630 treatment (P < 0.05; Fig. 4A ). Protein levels of both IL-1β and TNF-α in the pouches were also significantly increased in response to titanium particles (P < 0.05) and were also significantly reduced by treatment with AM630 (P < 0.05; Fig. 4B ).
Discussion
Approximately 1 million total joint replacements are carried out worldwide each year. 23 Total joint replacement is one of the most successful surgical procedures to be developed during the 20th Century; however, aseptic loosening of the prosthesis remains a major problem for many patients. 23 Up to Ti Ti + AM630 AM630 inhibits wear particle-induced inflammation 20% of patients with total joint arthroplasty will develop radiographic evidence of aseptic loosening, 24 which most likely results from an inflammatory response to billions of wear particles shed from the implant. 1, 3, 4 Recurrent painful effusions and loss of function indicate imminent pathological fracture or implant fracture caused by aseptic loosening or misalignment of the prosthesis and prompt revision surgery is usually indicated. For the patient who is minimally symptomatic but for whom the prosthesis is stable, wear is minimal but osteolysis can still be present; options for such patients include revision surgery or systemic and local treatments. Systemic and local treatments have shown some success in the laboratory, but none has been used successfully in the clinical arena. 5 − 9,25 − 28 Pre-clinical and clinical studies have demonstrated that cannabis-based drugs have therapeutic potential in inflammatory disease. 20, 21 It has been shown that CB 2 is critical in regulating the production of proinflammatory cytokines, such as TNF-α and IL-1β and nitric oxide. 20,21 AM630 constitutes a highly selective inhibitor of CB 2 , which can be used for direct identification of the effect of CB 2 on various cell types. The AM630 acts at the level of the CB 2 receptors on cell membranes, is capable of modulating intracellular signalling pathways and, as a result, influences gene expression thereby regulating cytokine production, apoptosis processes such as osteoclast differentiation. 12 − 14 There are no known adverse effects of treatment with AM630. 14 It has previously been demonstrated that CB 2 levels increase significantly following stimulation with titanium particles in the air-pouch model and that AM630 markedly reduces titanium particle-induced osteolysis. 19 It was, however, still unknown what role CB 2 played in the inflammation induced by wear particles. For this reason we set out to test the hypothesis that the CB 2selective antagonist AM630 diminishes the inflammatory reaction to wear particles and reduces the expression of pro-inflammatory cytokines, such as TNF-α and IL-1β, in vivo and in vitro.
Wear particles can stimulate macrophages to produce a multitude of pro-inflammatory cytokines, including TNF-α, IL-1β, IL-6, prostaglandin E 2 and peptides. 6 − 9,29 − 31 Only small particles, ranging from 0.2 to 10 µm in 32 The possible process of wear particle damage is that small particles are easily phagocytosed but unstable when digested by macrophages; these phagocytosed particles may then stimulate macrophages to produce numerous cytokines. 33 The present study indicates that titanium particles stimulate RAW264.7 cells to secrete the pro-inflammatory cytokines TNF-α, IL-1β and that treatment with AM630 significantly reduces the mRNA and protein levels of both these cytokines. These findings suggest that AM630 could effectively diminish the inflammatory reaction to wear particles in vitro.
In vivo, the wear particle-induced mouse air pouch osteolysis model is convenient for studying the mechanism of wear particleinduced osteoysis and the effect of drugs aimed at interfering with this process. 18,27 − 30 This animal model creates the formation of a surrounding fibrous layer containing abundant macrophages that have phagocytosed the wear particles, with elevated production of pro-inflammatory cytokines and increased osteoclast differentiation. 18 As previously reported, titanium particles implanted into the air pouch of BALB/c mice cause significant inflammatory reaction. 27, 30 The present study showed that AM630 treatment suppressed titanium particlestimulated tissue inflammation and reduced the levels of TNF-α and IL-1β in pouch tissues, further supporting the in vitro data. The reason why AM630 treatment significantly reduced pouch tissue inflammation might be due to diminishing inflammatory cytokine production or blocking of macrophage recruitment from the circulation via cytokine signalling.
The present study attempted to simulate conditions seen in clinical practice of a particle-induced chronic inflammatory and foreign body reaction prior to treatment. A limitation of the present study was that titanium particles were used rather than ultra-high molecular weight polyethylene, which is the most common type of orthopaedic wear particle in patients. 1, 3 It has been demonstrated, however, that titanium particles induce inflammatory reaction and osteolysis in bone tissue around prosthetic implants by mechanisms that are indistinguishable from polyethylene particles. 16, 18 Another major limitation is the murine air-pouch model itself, which induces acute inflammation rather than the chronic inflammation that is usually observed in aseptic loosening in the clinical settings. Thus, animal models reflecting wear-associated chronic inflammatory reactions are required to test the long-term effectiveness and safety of AM630 interventions.
In conclusion, the present study indicated that AM630 can effectively inhibit the inflammatory reaction to wear particles in vivo and in vitro. Meanwhile, it was previously demonstrated that the CB 2 -selective antagonist AM630 significantly diminished the levels of RANKL and RANK that had been stimulated using titanium particles in the airpouch model. 19 As such, the reduction of tissue inflammation and the blocking of RANKL/RANK signalling may be vital in preventing the progression of aseptic loosening. Thus, CB 2 -selective antagonists, like AM630, appear to be promising for prevention and treatment of inflammatory osteolysis induced by wear particles.
